KAPA
Kairos Pharma, Ltd. (KAPA) Risks & Opportunities Analysis (2026)
No material changes this month.
Risks
Extremely long cash conversion cycle versus peers suggests working-capital drag could constrain liquidity efficiency and amplify volatility if customer or supplier terms tighten.
Interest coverage is unavailable despite modest net debt, so financing flexibility appears harder to verify than for peers with clearer coverage and cash-flow disclosure.
Zero debt-to-equity alongside very high current ratio indicates balance-sheet conservatism, but it may also reflect limited capital deployment versus better-scaled peers.
Negative days payable outstanding and no inventory visibility imply operating data quality is opaque, which can reduce comparability versus peers and obscure margin resilience.
Opportunities
Net debt to EBITDA below 0.5x gives KAPA more financial flexibility than leveraged peers, supporting resilience if demand softens or working capital remains elevated.
Current and quick ratios near 12x materially exceed most peers, indicating strong short-term liquidity that can support operations and absorb external shocks.
Low leverage relative to peers can preserve optionality for growth investment or refinancing on favorable terms if market conditions improve.
If working-capital normalization follows the unusually long cash cycle, cash generation could improve faster than peers with tighter liquidity buffers.
Overall Score
KAPA’s strong liquidity and low leverage support peer-relative resilience, but the unusually long cash conversion cycle and limited coverage visibility keep forward positioning only moderately attractive.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Kairos Pharma, Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
